Schering AG/Berlex Angeliq second try
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG/Berlex expect a six-month review for Angeliq (drospirenone/estradiol) with the late March filing of a "complete response" for the hormone replacement therapy. Angeliq received a "not approvable" letter Oct. 17, 2002 in the wake of the Women's Health Initiative study results (1Pharmaceutical Approvals Monthly Nov. 1, 2002, In Brief). The firm is touting a potential anti-hypertensive effect with Angeliq...
You may also be interested in...
Berlex HRT agents "not approvable"
Schering AG U.S. subsidiary Berlex receives "not approvable" letter for hormone replacement therapy Angeliq (drosperinone) Oct. 17 and is seeking "active dialogue" to learn more about FDA's concerns. Schering AG is pointing to concerns about HRT raised in Women's Health Initiative study. The firm's estradiol/ levonorgestrel patch (formerly Climara) was deemed "not approvable" Oct. 8. FDA cited technical aspects of one of the clinical studies in the NDA, Berlex indicated. The patch received an earlier "not approvable" letter June 27, 200
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.